Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-03-27 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Receives Tentative Approval from U.S. FDA for Valbenazine Capsules.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Valbenazine Capsules. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or detailed investor presentation. The document length is 4045 characters, which is relatively short and consistent with a press release or regulatory disclosure. There is no financial data, no management discussion, no voting results, no audit information, and no mention of a report being attached or published. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-03-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Valbenazine Capsules. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. The document length is 4033 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. Therefore, this fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2023-03-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) at Lupin Limited's Pithampur facilities. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content focuses on regulatory inspection results and company compliance, without any financial data, detailed financial performance, or management discussion. The document length is 4163 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. It does not contain financial statements or substantive financial analysis, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure announcement about inspection results, which does not fit into other specific categories like Audit Report or Legal Proceedings Report.
2023-03-25 English
Lupin Announces Successful Completion of UK MHRA Inspection of its Pithampur Facilities.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) at Lupin Limited's Pithampur facilities. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The document is short (4165 characters) and primarily serves as an announcement of an event (inspection completion) rather than a detailed report or financial statement. There is no financial data, management discussion, or detailed report content. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure.
2023-03-25 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a U.S. FDA inspection with no observations. It is addressed to stock exchanges and references a regulatory disclosure under SEBI regulations. The content is a brief announcement about the inspection outcome and does not contain financial statements, detailed financial data, or management discussion. The document length is 4319 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full audit report, annual report, or earnings release. It is a regulatory disclosure announcement about an FDA inspection result, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-25 English
Lupin Announces Completion of Pharmacovigilance Inspection by the U.S. FDA with No Observations.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a U.S. FDA inspection with no observations. It is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is an announcement of an event (inspection completion) rather than a detailed report or financial statement. The document length is 4322 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial data, no detailed management discussion, no audit information, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2023-03-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.